Donga Socio Holdings - Asset Resilience Ratio
Donga Socio Holdings (000640) has an Asset Resilience Ratio of 1.85% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Donga Socio Holdings current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Donga Socio Holdings's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 000640 total assets.
Liquid Assets Composition Over Time
This chart breaks down Donga Socio Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Donga Socio Holdings long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩37.95 Billion | 1.85% |
| Total Liquid Assets | ₩37.95 Billion | 1.85% |
Asset Resilience Insights
- Limited Liquidity: Donga Socio Holdings maintains only 1.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Donga Socio Holdings Industry Peers by Asset Resilience Ratio
Compare Donga Socio Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Donga Socio Holdings (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Donga Socio Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | ₩9.95 Billion ≈ $6.75 Million |
₩2.03 Trillion ≈ $1.38 Billion |
-1.59pp |
| 2023-12-31 | 2.08% | ₩40.64 Billion ≈ $27.54 Million |
₩1.96 Trillion ≈ $1.33 Billion |
+1.46pp |
| 2022-12-31 | 0.61% | ₩10.63 Billion ≈ $7.20 Million |
₩1.73 Trillion ≈ $1.17 Billion |
-2.86pp |
| 2021-12-31 | 3.48% | ₩58.84 Billion ≈ $39.87 Million |
₩1.69 Trillion ≈ $1.15 Billion |
-0.21pp |
| 2020-12-31 | 3.68% | ₩55.67 Billion ≈ $37.73 Million |
₩1.51 Trillion ≈ $1.02 Billion |
-0.35pp |
| 2019-12-31 | 4.03% | ₩54.81 Billion ≈ $37.14 Million |
₩1.36 Trillion ≈ $920.69 Million |
+3.56pp |
| 2018-12-31 | 0.48% | ₩5.93 Billion ≈ $4.02 Million |
₩1.24 Trillion ≈ $841.64 Million |
+0.40pp |
| 2017-12-31 | 0.08% | ₩1.11 Billion ≈ $749.55K |
₩1.46 Trillion ≈ $989.05 Million |
-0.10pp |
| 2016-12-31 | 0.17% | ₩2.43 Billion ≈ $1.65 Million |
₩1.40 Trillion ≈ $950.26 Million |
-0.13pp |
| 2015-12-31 | 0.30% | ₩3.70 Billion ≈ $2.51 Million |
₩1.22 Trillion ≈ $829.16 Million |
+0.09pp |
| 2014-12-31 | 0.21% | ₩2.25 Billion ≈ $1.52 Million |
₩1.08 Trillion ≈ $732.63 Million |
-0.52pp |
| 2013-12-31 | 0.73% | ₩7.20 Billion ≈ $4.88 Million |
₩988.28 Billion ≈ $669.74 Million |
+0.52pp |
| 2012-12-31 | 0.21% | ₩3.59 Billion ≈ $2.43 Million |
₩1.72 Trillion ≈ $1.17 Billion |
-2.77pp |
| 2011-12-31 | 2.98% | ₩44.45 Billion ≈ $30.12 Million |
₩1.49 Trillion ≈ $1.01 Billion |
+2.16pp |
| 2010-12-31 | 0.82% | ₩10.09 Billion ≈ $6.84 Million |
₩1.23 Trillion ≈ $836.45 Million |
+0.66pp |
| 2009-12-31 | 0.16% | ₩1.69 Billion ≈ $1.14 Million |
₩1.06 Trillion ≈ $716.50 Million |
-0.43pp |
| 2008-12-31 | 0.59% | ₩4.52 Billion ≈ $3.06 Million |
₩769.94 Billion ≈ $521.78 Million |
-0.37pp |
| 2007-12-31 | 0.96% | ₩6.83 Billion ≈ $4.63 Million |
₩713.72 Billion ≈ $483.68 Million |
+0.05pp |
| 2006-12-31 | 0.91% | ₩6.62 Billion ≈ $4.49 Million |
₩731.74 Billion ≈ $495.89 Million |
-0.35pp |
| 2005-12-31 | 1.25% | ₩9.08 Billion ≈ $6.15 Million |
₩724.29 Billion ≈ $490.84 Million |
+0.04pp |
| 2004-12-31 | 1.21% | ₩8.56 Billion ≈ $5.80 Million |
₩706.01 Billion ≈ $478.45 Million |
-1.10pp |
| 2003-12-31 | 2.31% | ₩15.98 Billion ≈ $10.83 Million |
₩691.41 Billion ≈ $468.56 Million |
+0.08pp |
| 2002-12-31 | 2.23% | ₩13.18 Billion ≈ $8.93 Million |
₩590.72 Billion ≈ $400.32 Million |
-2.21pp |
| 2001-12-31 | 4.44% | ₩26.35 Billion ≈ $17.86 Million |
₩593.63 Billion ≈ $402.30 Million |
+0.49pp |
| 2000-12-31 | 3.95% | ₩21.63 Billion ≈ $14.66 Million |
₩547.36 Billion ≈ $370.94 Million |
-- |
About Donga Socio Holdings
Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of S… Read more